Privatizing biomedical research - a 'third way'

被引：13

作者：

Bouchard, Ron A. ^{[1
]}

Lemmens, Trudo ^{[2
]}

机构：

[1] Univ Alberta, Fac Law & Med & Dent, Edmonton, AB T6G 2H5, Canada

[2] Univ Toronto, Fac Law & Med, Toronto, ON M5S 2C5, Canada

来源：

NATURE BIOTECHNOLOGY | 2008年 / 26卷 / 01期

关键词：

D O I：

10.1038/nbt0108-31

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The allocation of risks and benefits of publicly sponsored biomedical research is becoming increasingly skewed toward for-profit entities and against the public interest. A legitimate solution to this imbalance would be to levy compulsory government royalty fees on commercial products made possible by public efforts.

引用

页码：31 / 36

页数：6

共 55 条

[1]

[Anonymous], 1997, Pasteur's quadrant: Basic science and technological innovation

[2]

[Anonymous], 1997, 6018 NBER

[3]

[Anonymous], MICHIGAN TELECOMMUNI

[4]

ARGYRES NS, 1988, J EC BEHAV ORGAN, V35, P427

[5]

Baker D, 2002, PROMOTING GOOD IDEAS

[6]

Bernstein A, 2003, CAN MED ASSOC J, V168, P288

[7]

BOUCHARD RA, 2008, HLTH LAW J

[8]

BOUCHARD RA, 2007, BOSTON U J SCI TECHN, V13, P121

[9]

Bouchard Ron A., 2007, U OTTAWA LAW TECHNOL, V4, P1

[10] Whose tissue is it anyway? [J].

Bovenberg, J .

NATURE BIOTECHNOLOGY, 2005, 23 (08) :929-933

← 1 2 3 4 5 6 →